Funds and ETFs Agios Pharmaceuticals, Inc.

Equities

AGIO

US00847X1046

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-02 pm EDT 5-day change 1st Jan Change
34.58 USD +2.73% Intraday chart for Agios Pharmaceuticals, Inc. +9.19% +55.28%
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
34.58 USD
Average target price
41.67 USD
Spread / Average Target
+20.49%
Consensus
  1. Stock Market
  2. Equities
  3. AGIO Stock
  4. Funds and ETFs Agios Pharmaceuticals, Inc.